Member Info for elrico

bp,

Likewise, I have the greatest respect for you because I know you consider your comments carefully without hinting at emotional hysteria. I hope that does not read as condescending.

We have both put our deliberation forward. It really comes down to one risk-weight. As I said, I am more forgiving in this case. And yes, I agree the error should not have occurred, and I appreciate your view. I am not suggesting your view is wrong, while my view is superior.

"I sincerely hope they have got a proper sales strategy in place and they will have the product in the right place and are selling through the right channels. "

If the acquisition is successful, they acquire the sales team along with existing channels, which include access to the NHS and national pharmacy channels, which should help with AxisBiotix Ps sales. Hopefully, this answers part of your concern.

It will be interesting to see how SBTX marketing and sales staff synergies evolve with the new team. There could be a lot to discuss on synergies and improving SBTX product awareness outside the UK. This must be an ambition.

In case you missed the Q&A there is more context on sales channels, etc.
https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-5a9

bp,

Every forum has bulls defending their investment; you may view this as partisan while ignoring some of the same bulls (on this forum) that have been openly critical of the CEO and CFO, as well as acute or perceived communication through RNS.

You seem unforgiving of mistakes that are not material in regards to costly financially. I agree it is a mistake that should not occur and will likely have a negative effect in some quarters. However, we need to understand a lot is happening behind the scenes, and mistakes sometimes slip by that otherwise would not.

In my view, there is a plausible explanation which I am willing to forgive and not overreact because I believe redemption is around the corner, and the CFO is integral to it.

The audit process the Company has to undergo as part of the acquisition process, therefore, has come to light. As a result, the operating loss has increased from £2,716k to £2,982k. However, as announced, this has no impact on the Group's year-end net cash position of £1.8 million. In addition, we know they are opening new territories, which increases the market potential from a low base. As such, any performance uplift on current revenue forecasts will result in a positive unwinding of the stock provision, enhancing earnings in FY23.

It is odd nobody has picked up on the last line. This suggests the board is not as partisan as you claim.

In addition, who knows how the acquisition will move the forecasts. A potential material even if it is accretive as implied.

Acknowledging SkinBioTherapeutics’ “solid platform”, Sederma Managing Director Arnaud Fournial said, “We believe the technology has the potential to become an essential and significant component of cosmetic products within the rapidly emerging skin microbiome market.”

Al,

Defo not barney with the missus. I just do as I'm told. Life is easier when I behave like a good little boy. I get treats as well! :)

I am confident Croda will change the flagging perception you mention. IMHO, the whole game could change if the M&A is completed without a hitch. A credible portfolio transforms SBTX fortunes years in advance. I look forward to discussing this in greater details as and when the Company provides more information.

It hinges on just how accretive this deal is? Net cash to the bottomline would be a worldy!

Al,

I think you have the memory of a goldfish with dementia where some previously discussed facts are concerned. :)

I can confirm Sederma provided a dozen or so VIP clients the lysate in 2022, thereafter, I believe in 2023 the lysate will be made available to ROW, if not already.

There used to be a reference to the size of Sederma's client portfolio on the Sederma site, but the site no longer exists, it is under the Croda portal now, but there is a client log-in portal, presumable for ordering.

There is a reference to Sederma's global client size in the following link, so, there is references to this.

"Croda and its active ingredient arm, Sederma, continues to progress the development of SkinBiotix® as the foundation for an active skincare ingredient for the cosmetic and skin care industry. Final scale-up to capacity required to mass produce the project is now being progressed and Croda has engaged with VIP clients within its portfolio of 12,000+ global cosmetic customers for its inclusion."

http://lifesciences.instinctif.com/news/2022/02/skinbiotherapeutics-plc-business-update-2022

My view is simple logic. I am not saying my reasoning is not flawed, but I'll own it!

I imagine the powerbrokers at Croda will have crunched some numbers based on 2-3 year sales targets they may have set for, say, 20% of Matryxl and dreamed up the need:

1: A dedicated production line for the lysate
2: Build a 20,000-litre vessel

Scale-up production to test QC, stability and possible adverse reactions or improvements during this task.

My NY wish is for Croda to provide a reasonable update in January and lob a few ferrets down the rabbit warren. :)

Al,

With respect, I must disagree with you. Your experience in a similar industry does not support your opinion. £5m is pocket change to Croda, so building a "dedicated production line" makes perfect sense given the downtime cleaning the line for another product. You have explained this in prior discussions, explaining the downtime and the cleaning process to minimise cross-contamination. This is all rather confusing, especially in light of what Stuart has said multiple times. Do you not think he would have clarified the same via Croda before making important claims?

Al,

We have been told countless times the new production line is solely for the purpose to produce the lysate, nothing else. Stuart discussed this at the Manchester meeting, you were there. :)

Friedman,

Care to share what I said was so compelling, and when? I’ve been critical of specifics throughout 2022, but at the same time being hopeful. I also declared I was going to sell my holding 48 hours before I did. And I explain why I before I did.

Ref accounting anomaly https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-a14

Plus, Q&A in case you have missed it. https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-5a9

Yes, it does. But their model is donations and kickbacks from partnerships.

Al,

There is a place for devil's advocate because, done correctly, it stimulates discussion, as you correctly point out. My issue is the same circular discussion about Axisales, NSF, disappointing sales, and prior forecasts; all have been discussed and addressed multiple times. They were also addressed in the podcast Toyin has provided many times before. Still, here we are yet again, regurgitating the same discussion when there are, IMHO, far more critical discussions to be had, and I have tried to lead the way by discussing the clues provided.

IMHO, if the M&A is complete, it transforms SBTX overnight and improves as the Company progresses with product development.

Al, you and your friends appear to be very short-sighted. The constant rearview with AxisBiotix sound like a strategy you and your friends have adopted for reasons only you can explain.

In one masterstroke AxisBiotix is listed on a portal with established traffic with an existing portfolio. The same will provide access to the database of its customers to which they can market AxisBiotix too. I am sure we will know this database's size in the full time. I guess it is multiples of what the Company has access to now.

I find your comment, "We know GPs cannot prescribe our products as not NHS (Nice) registered", bizarre because the Company SBTX is acquiring already has established brands inside the NNS and National pharmacy.

Stuart has explained the synergies very well. I know you to be an intelligent investor, but somehow, you wish to downplay the Corporate strategy with the constant threat you and your friends may bail. I am sure this is not your message, but people have commented on the "group think threat" to me.

Clio,

I was not paid or asked if my work could be used for another premium service. However, I am humble enough to be grateful.

I quite like Tom, so I will not sulk over it. It is as close to a compliment as I am likely to get! :)

https://tinyurl.com/muh677pk

On the other asylum, there has been a few questions regarding the time and fund of the target.
Is it fully funded?
Why mention it at all until it's concluded?

My reading, FWIW, is this.

IMHO the deal is done. The placing RNS was the assurance the seller needed to confirm SBTX has the funding required.

Is the funding enough? Not a scooby, but I'd be surprised if there were another placing RNS. That would be bad PR unless there is net cash positive gleaned from the accretive acquisition.

We don't know the acquisition. We know it has a broad portfolio that SBTX science and IP will be back into and establish NHS and national pharmacy sales. So, I guess any additional funding may well be via a mix of SBTX share options and a share of profits and/or earnouts.

I think the language in the RNS is on time and certainly is a smokescreen buried as it was by the broker, hoping at no one watching o'clock would notice it and, therefore, not a big issue made of it. But, some nosy little hobbit spotted it and ran with it. Just saying!

I wish you a joyous Christmas and a better 2023.
Thanks for your support.

Stuart said the Company does not need the £1m from the OO. The £2.5m is a different matter, of course. My reading between the lines (not guidance from Stuart) is he had to apply the same discount, which is not attractive because, as we know, we have been able to buy under the 16p offer or a tad higher.

If you believe the Company does not need the additional £1m, then we should be happy the total allocation has not been taken because there is less dilution. IMHO, I think the OO was a gesture because the parent Company has been guilty of not providing the same opportunity when it has raised funds in the past.

I confess to not taking up the offer. I added all the same.

Scinv_Temp,
No, your statement is laughable!
The announcement is all part of a PLC strategy that flags their work to potential partners while at the same time informing investors and potential investors (PR) of the vital work they are undertaking with their collaborative partners. It is a long-established PLC strategy some PLCs are better at than others.

It seems you have a lot to learn about the Corporate world.

Probably one of my most exciting Q&A with any CEO.
https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-5a9

Should up in the next 90 mins.